DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.

TitleDNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.
Publication TypeJournal Article
Year of Publication2010
AuthorsShaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A
JournalBlood
Volume116
Issue20
Paginatione81-9
Date Published2010 Nov 18
ISSN1528-0020
KeywordsDNA Methylation, Epigenesis, Genetic, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Gene Regulatory Networks, Genes, Neoplasm, Humans, Lymphoma, Large B-Cell, Diffuse, Signal Transduction, Tumor Necrosis Factor-alpha
Abstract

Expression profiling has shown 2 main and clinically distinct subtypes of diffuse large B-cell lymphomas (DLBCLs): germinal-center B cell-like (GCB) and activated B cell-like (ABC) DLBCLs. Further work has shown that these subtypes are partially characterized by distinct genetic alterations and different survival. Here, we show with the use of an assay that measures DNA methylation levels of 50,000 CpG motifs distributed among more than 14,000 promoters that these 2 DLBCL subtypes are also characterized by distinct epigenetic profiles. DNA methylation and gene expression profiling were performed on a cohort of 69 patients with DLBCL. After assigning ABC or GCB labels with a Bayesian expression classifier trained on an independent dataset, a supervised analysis identified 311 differentially methylated probe sets (263 unique genes) between ABC and GCB DLBCLs. Integrated analysis of methylation and gene expression showed a core tumor necrosis factor-α signaling pathway as the principal differentially perturbed gene network. Sixteen genes overlapped between the core ABC/GCB methylation and expression signatures and encoded important proteins such as IKZF1. This reduced gene set was an accurate predictor of ABC and GCB subtypes. Collectively, the data suggest that epigenetic patterning contributes to the ABC and GCB DLBCL phenotypes and could serve as useful biomarker.

DOI10.1182/blood-2010-05-285320
Alternate JournalBlood
PubMed ID20610814
PubMed Central IDPMC2993635
Grant ListK08 CA127353 / CA / NCI NIH HHS / United States
/ / Canadian Institutes of Health Research / Canada